PI3K inhibition sensitizes EGFR wild‑type NSCLC cell lines to erlotinib chemotherapy

Zhou,Xin; Wang,Xiaowen; Zhu,Hongge; Gu,Guomin; Zhan,Yiyi; Liu,Chunling; Sun,Gang

doi:10.3892/etm.2020.9441

PI3K inhibition sensitizes EGFR wild‑type NSCLC cell lines to erlotinib chemotherapy

Authors:
- Xin Zhou
- Xiaowen Wang
- Hongge Zhu
- Guomin Gu
- Yiyi Zhan
- Chunling Liu
- Gang Sun
View Affiliations

Affiliations: Department of Second Pulmonary Medicine, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China, Department of Second Breast Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China, Department of Breast, Head and Neck Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China
Published online on: November 4, 2020 https://doi.org/10.3892/etm.2020.9441
Article Number: 9
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tyrosine kinase inhibitors (TKIs) bring significant benefits for patients with cancers harboring epidermal growth factor receptor (EGFR) mutations. However, after treatment for a certain period, most patients ultimately acquire resistance. Numerous studies indicated that PI3K has an important role in tumor cell growth and drug sensitivity. Furthermore, inhibition of PI3K may lead to sensitization of non‑small cell lung cancer (NSCLC) cells to EGFR‑TKIs. The aim of the present study was to explore whether LY294002, an inhibitor of PI3K, is able to improve the sensitivity of NSCLC cell lines with wild‑type EGFR to the EGFR‑TKI erlotinib. An MTT assay was used to examine the effect of combined treatment with LY294002 and erlotinib on cell survival of two EGFR wild‑type NSCLC cell lines, NCI‑H661 and NCI‑H460. Furthermore, flow cytometry was used to assess apoptosis in NCI‑H661 and NCI‑H460 cells after treatment with erlotinib and LY294002. In addition, the expression of downstream proteins was detected by western blot analysis. The results indicated that the number of viable NCI‑H661 and NCI‑H460 cells was dose‑dependently reduced by erlotinib or LY294002. Compared to treatment with erlotinib alone, the cell apoptosis was enhanced if combined treatment of erlotinib and LY294002 was performed in NCI‑H661 cells. Furthermore, combination treatment of erlotinib and LY294002 resulted in a significant reduction of phosphorylated p70S6K levels in NCI‑H661 [PI3K catalytic subunit alpha (PI3KCA) wild‑type] cells. However, this phenomenon was not observed in the NCI‑H460 cell line (PIK3CA mutant‑type). In conclusion, the present study indicated that inhibition of PI3K may have the potential to improve the sensitivity of NSCLC cells to an EGFR‑TKI. However, the therapeutic effect may depend on the mutation status of PIK3CA.

View Figures

View References

1	Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL and Hurbin A: The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. Int J Cancer. 134:2560–2571. 2014.PubMed/NCBI View Article : Google Scholar
2	Mouradian M, Kikawa KD, Johnson ED, Beck KL and Pardini RS: Key roles forGRB2-associated-binding protein1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-inducedupregulation of lung and breast cancer cell growth. Prostaglandins Leukot Essent Fatty Acids. 90:105–115. 2014.PubMed/NCBI View Article : Google Scholar
3	Brückl W, Tufman A and Huber RM: Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: First-line treatment with afatinib and other EGFR TKIs. Expert Rev Anticancer Ther. 17:143–155. 2017.PubMed/NCBI View Article : Google Scholar
4	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004.PubMed/NCBI View Article : Google Scholar
5	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004.PubMed/NCBI View Article : Google Scholar
6	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009.PubMed/NCBI View Article : Google Scholar
7	Engelman JA and Settleman J: Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev. 18:73–79. 2008.PubMed/NCBI View Article : Google Scholar
8	Matikas A, Mistriotis D, Georgoulias V and Kotsakis A: Current and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR TKIs. Clin Lung Cancer. 16:252–261. 2015.PubMed/NCBI View Article : Google Scholar
9	Jakobsen KR, Demuth C, Sorensen BS and Nielsen AL: The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 5:172–182. 2016.PubMed/NCBI View Article : Google Scholar
10	Zhou Q, Yang JJ, Chen ZH, Zhang XC, Yan HH, Xu CR, Su J, Chen HJ, Tu HY, Zhong WZ, et al: Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. J Hematol Oncol. 9(86)2016.PubMed/NCBI View Article : Google Scholar
11	Gohr K, Hamacher A, Engelke LH and Kassack MU: Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. BMC Cancer. 17(711)2017.PubMed/NCBI View Article : Google Scholar
12	Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014.PubMed/NCBI View Article : Google Scholar
13	Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B and Zhou C: Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci. 56:275–284. 2011.PubMed/NCBI View Article : Google Scholar
14	Heavey S, O'Byrne KJ and Gately K: Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev. 40:445–456. 2014.PubMed/NCBI View Article : Google Scholar
15	Kang XH, Xu ZY, Gong YB, Wang L, Wang Z-Q, Xu L, Cao F and Liao M: Bufalin reverses HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via blockage of Met/PI3k/Akt pathway and induction of apoptosis. Evid Based Complement Alternat Med. 2013(243859)2013.PubMed/NCBI View Article : Google Scholar
16	Chen P, Wen X, Wang B, Hou D, Zou H, Yuan Q, Yang H, Xie J and Huang H: PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft. Ann Hematol. 97:865–875. 2018.PubMed/NCBI View Article : Google Scholar
17	Mao Y, Xi L, Li Q, Wang S, Cai Z, Zhang X and Yu C: Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma. Transl Oncol. 11:852–863. 2018.PubMed/NCBI View Article : Google Scholar
18	Wang Y, Kuramitsu Y, Baron B, Kitagawa T, Tokuda K, Akada J, Maehara SI, Maehara Y and Nakamura K: PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int J Oncol. 50:606–612. 2017.PubMed/NCBI View Article : Google Scholar
19	Russo A, Franchina T, Ricciardi GR, Picone A, Ferraro G, Zanghì M, Toscano G, Giordano A and Adamo V: A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget. 6:26814–26825. 2015.PubMed/NCBI View Article : Google Scholar
20	Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al: Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012.PubMed/NCBI View Article : Google Scholar
21	Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghì M, Rolfo C and Adamo V: Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. Crit Rev Oncol Hematol. 117:38–47. 2017.PubMed/NCBI View Article : Google Scholar
22	Camidge DR, Pao W and Sequist LV: Acquired resistance to TKIs in solid tumours: Learning from lung cancer. Nat Rev Clin Oncol. 11:473–481. 2014.PubMed/NCBI View Article : Google Scholar
23	Kuger S, Graus D, Brendtke R, Günther N, Katzer A, Lutyj P, Polat B, Chatterjee M, Sukhorukov VL, Flentje M, et al: Radiosensitization of glioblastoma cell lines by the dual PI3K and mTOR inhibitor NVP-BEZ235 depends on drug-irradiation schedule. Transl Oncol. 6:169–179. 2013.PubMed/NCBI View Article : Google Scholar
24	Xie X, Tang B, Zhou J, Gao Q and Zhang P: Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep. 30:773–782. 2013.PubMed/NCBI View Article : Google Scholar